© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Lonza Group AG (LZAGY) stock declined over -0.28%, trading at $71.07 on OTC, down from the previous close of $71.27. The stock opened at $70.80, fluctuating between $70.41 and $71.16 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Jul 08, 2026 | 70.80 | 71.16 | 70.41 | 71.07 | 50.66K |
| Jul 07, 2026 | 72.08 | 72.08 | 70.91 | 70.96 | 41.93K |
| Jul 06, 2026 | 72.01 | 72.27 | 71.20 | 72.25 | 82.77K |
| Jul 02, 2026 | 70.58 | 70.75 | 69.96 | 70.43 | 74.12K |
| Jul 01, 2026 | 68.48 | 69.77 | 68.47 | 69.58 | 36.46K |
| Jun 30, 2026 | 67.45 | 67.86 | 67.25 | 67.50 | 25.41K |
| Jun 29, 2026 | 66.44 | 66.96 | 66.15 | 66.90 | 35.5K |
| Jun 26, 2026 | 65.88 | 66.40 | 65.77 | 65.94 | 25.07K |
| Jun 25, 2026 | 65.90 | 66.70 | 65.90 | 66.32 | 22.57K |
| Jun 24, 2026 | 65.40 | 65.43 | 64.84 | 64.92 | 29.96K |
| Jun 23, 2026 | 63.64 | 64.05 | 63.32 | 63.74 | 76.63K |
| Jun 22, 2026 | 61.93 | 62.12 | 61.42 | 61.97 | 126.59K |
| Jun 18, 2026 | 60.72 | 61.38 | 60.69 | 61.20 | 41.17K |
| Jun 17, 2026 | 61.79 | 62.30 | 61.17 | 61.22 | 68.91K |
| Jun 16, 2026 | 62.76 | 62.77 | 62.04 | 62.24 | 34.8K |
| Jun 15, 2026 | 62.86 | 62.99 | 62.06 | 62.14 | 60.22K |
| Jun 12, 2026 | 61.40 | 61.67 | 60.91 | 61.53 | 40.4K |
| Jun 11, 2026 | 62.02 | 62.70 | 61.39 | 62.41 | 140.96K |
| Jun 10, 2026 | 62.25 | 62.50 | 61.78 | 61.78 | 52.74K |
| Jun 09, 2026 | 61.63 | 62.49 | 61.63 | 62.26 | 63.84K |
Lonza Group AG engages in the supply of pharmaceutical, healthcare, and life science products. It operates through the following segments: Biologics, Small Molecules, Cell and Gene, Capsule and Health Ingredients, and Corporate. The Biologics segment serves as contract development and manufacturing partner for biopharmaceuticals, catering customers for all clinical and commercial manufacturing needs throughout the product lifecycle. The Small Molecules segment design, development, and manufacturing, with the ability to offer integrated drug substances to drug product solutions, including particle engineering and drug product packaging. The Cell and Gene segment develops, de-risk, commercializes, and scales their emerging therapies through its three business areas Cell and Gene Technologies, Bioscience, and Personalized Medicine. The Capsule and Health Ingredients segment provides innovative capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical companies. The Corporate segment refers to finance and accounting, legal, communication, information technology, and human resources functions. The company was founded on October 27, 1897 and is headquartered in Basel, Switzerland.
| Employees | 16866 |
| Beta | 0.83 |
| Sales or Revenue | $6.57B |
| 5Y Sales Change% | 0.225% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |